Therapeutic Targets Database
BIDD Pharmainformatics Databases


Target Validation Information
Target NamePeroxisome proliferator activated receptor gamma    
Type of TargetSuccessful target    
Drug Potency against TargetRosiglitazoneEC50 = 40 nM[1]
PioglitazoneEC50 = 580 nM[1]
NetoglitazoneEC50 = 100 nM[2]
Rosiglitazone XREC50 = 200 nM[3]
Rosiglitazone & metforminEC50 = 200 nM[3]
Rosiglitazone & simvastatinEC50 = 200 nM[3]
Rosiglitazone & simvastatinIC50 = 23 nM[4]
Ref 1Curr Top Med Chem. 2005;5(3):265-82.Nuclear receptors as potential targets for modulating reverse cholesterol transport. To Reference
Ref 2Expert Opin Investig Drugs. 2003 Apr;12(4):623-33.Treatment of non-insulin-dependent diabetes mellitus. To Reference
Ref 3J Biol Chem. 1998 Dec 4;273(49):32679-84.A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. To Reference
Ref 4Curr Opin Pharmacol. 2005 Aug;5(4):366-73.Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. To Reference
Ref 5J Med Chem. 2004 Aug 12;47(17):4118-27.Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543